Old Well Partners’s Prelude Therapeutics PRLD Stock Holding History

Old Well Partners’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,450	Closed	-$247K	–	51
2020 Q4	$247K	Buy	+3,450	New	+$172K	0.13%	32

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Old Well Partners's PRLD Position: Q1 2021 in Review

Old Well Partners sold out of Prelude Therapeutics (PRLD) in Q1 2021, closing a stake of 3,450 shares — an estimated $247K sold.

Old Well Partners first reported a position in PRLD in Q4 2020 and held it in 1 quarter. The position peaked at $247K in Q4 2020. 60 funds tracked by Wall St. Rank hold PRLD as of Q1 2021.

Old Well Partners reported no remaining Prelude Therapeutics position as of Q1 2021 after selling out during the quarter.
Old Well Partners sold 3,450 Prelude Therapeutics shares in Q1 2021, an estimated $247K.
Old Well Partners first reported a position in Prelude Therapeutics in Q4 2020 and held it in 1 quarter.
Old Well Partners's Prelude Therapeutics position peaked at $247K in Q4 2020.
60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2021.

Based on Old Well Partners's 13F filing for Q1 2021, filed 17 May 2021.